Thiogenesis Announces Investor Relations Engagement
San Diego, California--(Newsfile Corp. - September 27, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing thiol-active compounds that have strong antioxidant and anti-inflammatory properties and that have the potential to treat mitochondrial diseases, including metabolic syndrome, today announced that it has entered into an investor relations agreement (the IR Agreement), effective October 1, 2024, with Triomphe Holdings Ltd., doing business as Capital Analytica (Consultant).The services to be provided by the Consultant include...
2024-09-27 10:00 AM EDT
Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium
San Diego, California--(Newsfile Corp. - September 17, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that Patrice Rioux, M.D., Ph.D., the Company's Chief Executive Officer, has been invited to present this week at the Cure Mito Foundation's "Empower and Inspire: 3rd Annual Leigh Syndrome Symposium." The Cure Mito Foundation is a global non-profit patient advocacy organization...
2024-09-17 9:30 AM EDT
Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program
San Diego, California--(Newsfile Corp. - August 20, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that it has signed a Collaborative Agreement with the University of California San Diego ("UCSD"). Thiogenesis will work with Jeffrey Schwimmer, M.D., as the Principal Investigator at UCSD, in a proposed Phase 2 clinical trial titled: ...
2024-08-20 9:00 AM EDT
Thiogenesis Announces Leigh Syndrome Clinical Program
San Diego, California--(Newsfile Corp. - July 18, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that it has signed a Master Research Agreement with a leading U.S. pediatric hospital. In the agreement, the pediatric hospital will act as the Investigator in assessing Thiogenesis' lead compound, TTI-0102, in the rare mitochondrial disease Leigh syndrome. Leigh Syndrome and...
2024-07-18 9:00 AM EDT
Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS
San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and that have the potential to treat unmet pediatric diseases, today announced that the European Medicines Agency ("EMA") has accepted its Clinical Trial Application ("CTA") Part I - Scientific and Medicinal Product Documentation, for its lead compound TTI-0102, to commence a Phase 2 clinical trial for...
2024-03-25 9:00 AM EDT
Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement
San Diego, California--(Newsfile Corp. - December 20, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that, further to its news release of December 18, 2023, it has closed a second and final tranche of its non-brokered private placement, originally announced on November 20, 2023 (the "Offering"). Under this second tranche, the Company has issued 417,000 common shares for gross proceeds of C$312,750. The Company paid cash finder's fees of $21,892 and issued...
2023-12-20 9:00 AM EST
Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation
San Diego, California--(Newsfile Corp. - December 18, 2023) - Further to its news release of November 20, 2023, Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that it has closed a non-brokered private placement (the "Offering") through the issuance of 5,584,167 common shares (the "Offered Shares") for gross proceeds of $4,188,125.In connection with closing, the Company paid aggregate cash finder's fees of $285,294 and issued an aggregate of 380,392 non-transferable finders' options to eligible...
2023-12-18 12:00 PM EST
Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium
San Diego, California--(Newsfile Corp. - December 4, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company that is developing sulfur-containing compounds for unmet pediatric diseases, announced today that its CEO, Dr. Patrice Rioux, has been invited to lead a roundtable discussion on redox signaling at the 6th Annual Mitochondria Symposium at UCLA, in Los Angeles, California, on December 8, 2023.Reactive oxygen species ("ROS") have multiple biological functions. Importantly, they act as signaling molecules in...
2023-12-04 9:00 AM EST
Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board
San Diego, California--(Newsfile Corp. - November 27, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for unmet pediatric diseases, today announced the addition of Vincent Stanton Jr., MD to its Scientific Advisory Board ("SAB"). Dr. Stanton was a co-founder of Thiogenesis Therapeutics, Inc., dating back to February 2016.Dr. Vincent Stanton Jr., MD is an entrepreneur and consultant who has worked for a variety of diagnostics and therapeutics clients on...
2023-11-27 9:00 AM EST
Thiogenesis Announces Non-Brokered Private Placement of Common Shares
San Diego, California--(Newsfile Corp. - November 20, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") announced today that it will undertake a non-brokered private placement of $4.5 million (the "Offering") through the issuance of 6,000,000 common shares of the Company ("Offered Shares") at a price of $0.75 per Common Share.This Offering is subject to the approval of the TSX Venture Exchange (the "Exchange"). The Company anticipates closing of the Offering as soon as practicable subject to receipt...
2023-11-20 9:00 AM EST
Thiogenesis Therapeutics Reports on Full Year 2022 Financial Results and Provides Corporate Update
San Diego, California--(Newsfile Corp. - May 10, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing thiol-active compounds for unmet pediatric diseases, today reports on full year 2022 financial results and provides a corporate update.Patrice Rioux, M.D., Ph.D., Thiogenesis' founder and Chief Executive Officer stated, "We are pleased to report on a very eventful 2022, including: completing a going public transaction through a reverse takeover leading to the listing of our shares on...
2023-05-10 9:00 AM EDT
Thiogenesis Announces Stock Option Grants
San Diego, California--(Newsfile Corp. - December 9, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that it has granted an aggregate of 450,000 incentive stock options (the "Options") pursuant to the Company's stock option plan of which 350,000 were granted to directors and officers and 100,000 to a consultant. Each Option entitles the optionee to acquire one common share of the Company at an exercise price of $0.60 per common share until December...
2022-12-09 10:00 AM EST
Thiogenesis Announces Closing of Oversubscribed $5.3 Million Non-Brokered Private Placement
San Diego, California--(Newsfile Corp. - November 21, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce today, further to its news releases of October 24 and November 2, 2022, that it has closed an over-subscribed non-brokered private placement (the "Offering") through the issuance of 10,619,400 common shares (the "Offered Shares") in the capital of the Company for gross proceeds of $5,309,700 at a price of $0.50 per Offered Share.All securities issued and issuable...
2022-11-21 10:45 AM EST
Thiogenesis Announces Increase in Offering Size for Non-Brokered Private Placement of Common Shares
San Diego, California--(Newsfile Corp. - November 2, 2022) - Further to its news release of October 24, 2022, Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that, due to strong investor demand, it has increased the size of the non-brokered private placement from $4 million to $5.3 million (the "Offering") through the issuance of up to 10,600,000 common shares of the Company ("Offered Shares") at a price of $0.50 per share in the manner previously...
2022-11-02 7:30 AM EDT
Thiogenesis Announces Non-Brokered Private Placement of Common Shares
San Diego, California--(Newsfile Corp. - October 24, 2022) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") announced today that it will undertake a non-brokered private placement to raise up to $4 million (the "Offering") through the issuance of up to 8,000,000 common shares of the Company ("Offered Shares") at a price of $0.50 per Common Share.This Offering is subject to the approval of the TSX Venture Exchange ("Exchange"). The Company anticipates closing of the Offering as soon as...
2022-10-24 9:00 AM EDT
Thiogenesis Adopts New Equity Incentive Plan
San Diego, California--(Newsfile Corp. - October 17, 2022) - Thiogenesis Therapeutics Corp. (TSXV: TTI) (Thiogenesis or the Company) is pleased to announce that the TSX Venture Exchange (the "Exchange") has accepted for filing, the Company's new incentive stock option plan (the "2022 Plan"). The 2022 Plan replaces the Company's previous 10% rolling stock option plan (the "Old Plan").The 2022 Plan is a "fixed" plan, such that the aggregate number of common shares that may be issued upon the exercise or...
2022-10-17 6:22 PM EDT
Thiogenesis Announces Results from Annual and Special Meeting of Shareholders
San Diego, California--(Newsfile Corp. - September 26, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that shareholders have approved all matters put forward at its Annual and Special Meeting ("ASM") held on September 19th, 2022.All five members of the Company's board of directors, Dr. Patrice Rioux, Dr. Christopher Starr, Kim Tsuchimoto, Hogan Mullally and Brook Riggins, named as nominees in the Company's management information circular dated August 15, 2022, were elected as directors:...
2022-09-26 9:30 AM EDT
Thiogenesis Announces the Formation of its Scientific Advisory Board
San Diego, California--(Newsfile Corp. - August 30, 2022) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for unmet pediatric diseases today announced the formation of its Scientific Advisory Board ("SAB"). The SAB members are acclaimed leaders in their fields and will provide strategic guidance utilizing their vast experience to support the successful clinical and commercial development of Thiogenesis' proprietary, novel thiol-active compounds.Dr. Gregory Enns is a professor of Pediatrics in...
2022-08-30 9:00 AM EDT
Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102
Data demonstrates potential for less frequent drug administrationTTI-0102 was well tolerated with no Serious Adverse Events reportedSupports EU and US regulatory submissions for human efficacy trials in multiple disease indicationsSan Diego, California--(Newsfile Corp. - May 18, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for serious pediatric diseases, today announces positive results from its Phase 1 clinical study of oral TTI-0102 in healthy volunteers in Australia.The Phase 1, "O
2022-05-18 9:00 AM EDT
CORRECTION FROM SOURCE: Thiogenesis Therapeutics, Corp. Announces Closing of Qualifying Transaction
A correction from Thiogenesis Therapeutics, Corp. is issued for its news release of April 5, 2022. The news release has been corrected for the number of shares now held by Vincent Stanton, Jr. under the subheading "Early Warning Disclosure Pursuant to National Instrument 62-103". The corrected release is as follows:Toronto, Ontario--(Newsfile Corp. - April 5, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("TTI" or the "Company") (formerly Rozdil Capital Corporation) is pleased to announce that on March 31, 2022, it...
2022-04-05 11:19 PM EDT